Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for the capitalized costs to acquire rights under a license arrangement (for example, to sell specified products in a specified territory) having an indefinite period of benefit.

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(15))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_IndefiniteLivedLicenseAgreements
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(6))
-SubTopic 10
-Topic 220
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Name:	us-gaap_LegalFees
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of cash outflow for fees classified as other.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (g)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-25

+ Details

Name:	us-gaap_PaymentsForFees
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483041/730-20-50-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 730
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483041/730-20-50-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479532/912-730-25-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Name:	us-gaap_RoyaltyExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represent the amount of additional milestone payments.

+ References

No definition available.

+ Details

Name:	vrpx_AdditionalMilestonePayments
Namespace Prefix:	vrpx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Aggregate milestone payments

+ References

No definition available.

+ Details

Name:	vrpx_AggregateMilestonePayments
Namespace Prefix:	vrpx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represent the amount of milestone payments.

+ References

No definition available.

+ Details

Name:	vrpx_MilestonePayments
Namespace Prefix:	vrpx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represent the notice period for terminating.

+ References

No definition available.

+ Details

Name:	vrpx_NoticePeriodForTerminating
Namespace Prefix:	vrpx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of royalties

+ References

No definition available.

+ Details

Name:	vrpx_PercentageOfRoyalties
Namespace Prefix:	vrpx_
Data Type:	dtr:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Profit share arrangement percentage.

+ References

No definition available.

+ Details

Name:	vrpx_ProfitShareArrangementPercentage
Namespace Prefix:	vrpx_
Data Type:	dtr:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The amounnt of service fees.

+ References

No definition available.

+ Details

Name:	vrpx_ServiceFees
Namespace Prefix:	vrpx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represent the amount of upfront milestone payment.

+ References

No definition available.

+ Details

Name:	vrpx_UpfrontMilestonePayment
Namespace Prefix:	vrpx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=vrpx_MedPharmLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=vrpx_NanomericsCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=vrpx_AmendedNanomericsLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=vrpx_NanomericsLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=vrpx_YissumResearchAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_EquitySecuritiesByIndustryAxis=vrpx_CommercialMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	vrpx_AgreementAxis=vrpx_LipocureAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Research and Development and License Agreements (Details) £ in Thousands										3 Months Ended
	Mar. 27, 2024 USD ($)	Jan. 01, 2024 USD ($)	Feb. 01, 2023 USD ($)	Jan. 31, 2023 USD ($)	Apr. 21, 2022 USD ($)	Mar. 09, 2022 USD ($)	Sep. 17, 2021 USD ($)	Mar. 19, 2018 USD ($)	Jun. 06, 2017 GBP (£)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)
Research and Development and License Agreements [Line Items]
Upfront fee			$ 1,286,000	$ 326,000				$ 150,000
Milestone payments								$ 150,000
Notice period for terminating								90 days
License agreement												$ 1,500,000
Service fees		$ 343,467
Research and development expenses										$ 1,613,275	$ 1,235,614
Research service fees	$ 1,845,260
License [Member]
Research and Development and License Agreements [Line Items]
Milestone payments								$ 300,000
MedPharm License Agreement [Member]
Research and Development and License Agreements [Line Items]
Aggregate milestone payments (in Pounds) \| £									£ 1,150
Nanomerics Collaboration Agreement [Member]
Research and Development and License Agreements [Line Items]
Milestone payments										103,000,000
Amended Nanomerics License Agreement [Member]
Research and Development and License Agreements [Line Items]
Milestone payments						$ 5,500,000
Additional milestone payments						999,999
Nanomerics License Agreement [Member]
Research and Development and License Agreements [Line Items]
Milestone payments					$ 500,000
Upfront milestone payment							$ 200,000
Yissum Research Agreement [Member]
Research and Development and License Agreements [Line Items]
Upfront fee				$ 81,500
Research and development expenses										85,867	81,500
Commercial Milestone [Member] \| Amended Nanomerics License Agreement [Member]
Research and Development and License Agreements [Line Items]
Milestone payments						$ 112,500,000
Commercial Milestone [Member] \| Nanomerics License Agreement [Member]
Research and Development and License Agreements [Line Items]
Royalty payments							$ 41,000,000
Maximum [Member]
Research and Development and License Agreements [Line Items]
Milestone payments								$ 19,800,000
Maximum [Member] \| Amended Nanomerics License Agreement [Member]
Research and Development and License Agreements [Line Items]
Profit share arrangement percentage						40.00%
Percentage of royalties						15.00%
Maximum [Member] \| Nanomerics License Agreement [Member]
Research and Development and License Agreements [Line Items]
Percentage of royalties							15.00%
Minimum [Member] \| Amended Nanomerics License Agreement [Member]
Research and Development and License Agreements [Line Items]
Profit share arrangement percentage						30.00%
Percentage of royalties						5.00%
Minimum [Member] \| Nanomerics License Agreement [Member]
Research and Development and License Agreements [Line Items]
Percentage of royalties							5.00%
Lipocure Agreement [Member]
Research and Development and License Agreements [Line Items]
Upfront fee			$ 321,500
Research and development expenses										$ 711,315	$ 270,000